Neurodegeneration caused by expression of human truncated tau leads to progressive neurobehavioural impairment in transgenic rats - PubMed (original) (raw)
Neurodegeneration caused by expression of human truncated tau leads to progressive neurobehavioural impairment in transgenic rats
Miroslava Hrnkova et al. Brain Res. 2007.
Abstract
Human truncated tau protein is an active constituent of the neurofibrillary degeneration in sporadic Alzheimer's disease. We have shown that modified tau protein, when expressed as a transgene in rats, induced AD characteristic tau cascade consisting of tau hyperphosphorylation, formation of argyrophilic tangles and sarcosyl-insoluble tau complexes. These pathological changes led to the functional impairment characterized by a variety of neurobehavioural symptoms. In the present study we have focused on the behavioural alterations induced by transgenic expression of human truncated tau. Transgenic rats underwent a battery of behavioural tests involving cognitive- and sensorimotor-dependent tasks accompanied with neurological assessment at the age of 4.5, 6 and 9 months. Behavioural examination of these rats showed altered spatial navigation in Morris water maze resulting in less time spent in target quadrant (p<0.05) and fewer crossings over previous platform position (p<0.05) during probe trial. Spontaneous locomotor activity and anxiety in open field was not influenced by transgene expression. However beam walking test revealed that transgenic rats developed progressive sensorimotor disturbances related to the age of tested animals. The disturbances were most pronounced at the age of 9 months (p<0.01). Neurological alterations indicating impaired reflex responses were other added features of behavioural phenotype of this novel transgenic rat. These results allow us to suggest that neurodegeneration, caused by the non-mutated human truncated tau derived from sporadic human AD, result in the neuronal dysfunction consequently leading to the progressive neurobehavioural impairment.
Similar articles
- Impaired spatial reference memory and increased exploratory behavior in P301L tau transgenic mice.
Pennanen L, Wolfer DP, Nitsch RM, Götz J. Pennanen L, et al. Genes Brain Behav. 2006 Jul;5(5):369-79. doi: 10.1111/j.1601-183X.2005.00165.x. Genes Brain Behav. 2006. PMID: 16879631 - Truncated tau from sporadic Alzheimer's disease suffices to drive neurofibrillary degeneration in vivo.
Zilka N, Filipcik P, Koson P, Fialova L, Skrabana R, Zilkova M, Rolkova G, Kontsekova E, Novak M. Zilka N, et al. FEBS Lett. 2006 Jun 26;580(15):3582-8. doi: 10.1016/j.febslet.2006.05.029. Epub 2006 May 22. FEBS Lett. 2006. PMID: 16753151 - Truncated tau expression levels determine life span of a rat model of tauopathy without causing neuronal loss or correlating with terminal neurofibrillary tangle load.
Koson P, Zilka N, Kovac A, Kovacech B, Korenova M, Filipcik P, Novak M. Koson P, et al. Eur J Neurosci. 2008 Jul;28(2):239-46. doi: 10.1111/j.1460-9568.2008.06329.x. Eur J Neurosci. 2008. PMID: 18702695 - Misfolded tau protein and disease modifying pathways in transgenic rodent models of human tauopathies.
Zilka N, Korenova M, Novak M. Zilka N, et al. Acta Neuropathol. 2009 Jul;118(1):71-86. doi: 10.1007/s00401-009-0499-y. Epub 2009 Feb 24. Acta Neuropathol. 2009. PMID: 19238406 Review. - Argyrophilic grain disease.
Ferrer I, Santpere G, van Leeuwen FW. Ferrer I, et al. Brain. 2008 Jun;131(Pt 6):1416-32. doi: 10.1093/brain/awm305. Epub 2008 Jan 29. Brain. 2008. PMID: 18234698 Review.
Cited by
- Cellular Models of Aggregation-dependent Template-directed Proteolysis to Characterize Tau Aggregation Inhibitors for Treatment of Alzheimer Disease.
Harrington CR, Storey JM, Clunas S, Harrington KA, Horsley D, Ishaq A, Kemp SJ, Larch CP, Marshall C, Nicoll SL, Rickard JE, Simpson M, Sinclair JP, Storey LJ, Wischik CM. Harrington CR, et al. J Biol Chem. 2015 Apr 24;290(17):10862-75. doi: 10.1074/jbc.M114.616029. Epub 2015 Mar 10. J Biol Chem. 2015. PMID: 25759392 Free PMC article. - Enhanced tau phosphorylation in the hippocampus of mice treated with 3,4-methylenedioxymethamphetamine ("Ecstasy").
Busceti CL, Biagioni F, Riozzi B, Battaglia G, Storto M, Cinque C, Molinaro G, Gradini R, Caricasole A, Canudas AM, Bruno V, Nicoletti F, Fornai F. Busceti CL, et al. J Neurosci. 2008 Mar 19;28(12):3234-45. doi: 10.1523/JNEUROSCI.0159-08.2008. J Neurosci. 2008. PMID: 18354027 Free PMC article. - The rat as an animal model of Alzheimer's disease.
Benedikz E, Kloskowska E, Winblad B. Benedikz E, et al. J Cell Mol Med. 2009 Jun;13(6):1034-42. doi: 10.1111/j.1582-4934.2009.00781.x. Epub 2009 May 11. J Cell Mol Med. 2009. PMID: 19432812 Free PMC article. - Tau Protein Hyperphosphorylation and Aggregation in Alzheimer's Disease and Other Tauopathies, and Possible Neuroprotective Strategies.
Šimić G, Babić Leko M, Wray S, Harrington C, Delalle I, Jovanov-Milošević N, Bažadona D, Buée L, de Silva R, Di Giovanni G, Wischik C, Hof PR. Šimić G, et al. Biomolecules. 2016 Jan 6;6(1):6. doi: 10.3390/biom6010006. Biomolecules. 2016. PMID: 26751493 Free PMC article. Review. - Interleukin33 deficiency causes tau abnormality and neurodegeneration with Alzheimer-like symptoms in aged mice.
Carlock C, Wu J, Shim J, Moreno-Gonzalez I, Pitcher MR, Hicks J, Suzuki A, Iwata J, Quevado J, Lou Y. Carlock C, et al. Transl Psychiatry. 2017 Jul 4;7(7):e1164. doi: 10.1038/tp.2017.142. Transl Psychiatry. 2017. PMID: 28675392 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical